Lifesci Capital Raises Earnings Estimates for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Lifesci Capital boosted their FY2024 earnings per share (EPS) estimates for Disc Medicine in a report released on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($3.92) for the year, up from their prior forecast of ($4.33). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share. Lifesci Capital also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.94) EPS.

Several other analysts have also recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. HC Wainwright increased their price objective on Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a research report on Wednesday. Scotiabank boosted their target price on Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Wells Fargo & Company began coverage on Disc Medicine in a report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price target on the stock. Finally, Jefferies Financial Group started coverage on Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $85.80.

Disc Medicine Trading Down 2.0 %

Shares of Disc Medicine stock opened at $59.46 on Friday. The company’s 50-day moving average price is $51.20 and its 200-day moving average price is $45.09. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -14.94 and a beta of 0.60. Disc Medicine has a 12-month low of $25.60 and a 12-month high of $77.60.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15.

Institutional Trading of Disc Medicine

Hedge funds have recently added to or reduced their stakes in the business. Atlas Venture Life Science Advisors LLC increased its holdings in shares of Disc Medicine by 9.7% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company’s stock worth $113,101,000 after buying an additional 222,223 shares during the period. Wellington Management Group LLP increased its stake in Disc Medicine by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock worth $90,429,000 after purchasing an additional 83,731 shares during the period. Frazier Life Sciences Management L.P. lifted its position in Disc Medicine by 123.5% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after purchasing an additional 969,834 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of Disc Medicine by 53.8% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after purchasing an additional 357,730 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Disc Medicine by 59.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after purchasing an additional 353,382 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Insider Activity at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 7,538 shares of company stock valued at $437,875. Corporate insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.